New pricing agreement in France includes provisions on biosimilars pricing for the first time.
By EsqSocial Corporation 25/03/21
On 5 March 2021, the President of the Economic Committee for Health Products (CEPS) and the President of the French pharmaceutical industry association (Leem) signed a new three-year framework agreement in the presence of the French Minister of Health. This framework agreement defines conventionally the rules for setting the price of medicinal products in compliance with the legislative framework and includes for the first time provisions on biosimilar pricing. It is one of the essential tools...
By: Allen & Overy LLP